A nanomedicine encapsulating a docetaxel prodrug, and conjugated to an antibody specific for the receptor EphA2, provides enhanced antitumour activity in multiple tumour-xenografted mice, and has minimal toxicity in rats and dogs.
- Walid S. Kamoun
- Dmitri B. Kirpotin
- Daryl C. Drummond